Redwire Corporation (RDW): NASA Awards Additional $4 million to Support New Drug Development Investigations

Group 1 - Redwire Corporation (NYSE:RDW) has been identified as one of the 12 Most Shorted Stocks to Buy in 2026, indicating potential investment interest [1] - NASA has awarded an additional $4 million to Redwire to support new drug development investigations on the International Space Station (ISS) using its Pharmaceutical In-space Laboratory (PIL-BOX) technology [1][6] - The additional funding has led to an expansion of an existing task order under a $25 million, 5-year indefinite-delivery/indefinite-quantity contract through NASA's In Space Production Applications (InSPA) program, highlighting the role of NASA as a catalyst for new capabilities in both public and private sectors [2] Group 2 - Truist upgraded Redwire's stock rating from "Hold" to "Buy," increasing the price target from $13 to $15, citing improvements in program mix and visibility on cost charges [3] - The new CFO of Redwire has set low and achievable targets for 2026, which may contribute to investor confidence [3] - Redwire Corporation provides critical space solutions and infrastructure for government and commercial customers, positioning itself in a growing industry [4]